ArticleJournal of surgical oncology2025
The Burden of Colorectal Cancer Treatment on Quality of Life: A Paired Longitudinal Analysis of Medicare Advantage Enrollees.
Article in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivesTreatment of colorectal cancer (CRC) can have prolonged effects on health-related quality of life (HRQOL). Using the Medicare Health Outcomes Survey (MHOS), this study examines HRQOL outcomes among those undergoing CRC treatment and those who completed CRC treatment.
methodsWe performed a paired longitudinal retrospective cohort study of Medicare Advantage enrollees ≥ 65 years of age who completed the baseline and follow-up MHOS from 2016 to 2020 and answered survey questions regarding current CRC treatment. Outcomes included Physical Component Summary (PCS) scores and Mental Component Summary (MCS) scores. Multivariable logistic regression analyses were used.
results574 Respondents met the inclusion criteria. Those currently undergoing treatment for CRC had significantly lower PCS scores (β coefficient -3.08 points, p < 0.001) and significantly lower MCS scores (β coefficient -1.40 points, p = 0.008) at follow-up compared to when they were not undergoing CRC treatment at baseline. Respondents who completed CRC treatment had PCS and MCS scores that remained similar over time (β coefficient 0.54 points, p = 0.466 and 0.07 points, p = 0.924, respectively). DISCUSSION: Treatment of CRC negatively influences HRQOL. These findings emphasize the importance of informing patients of the long-term effects of CRC treatment and support the implementation of interventions aimed at providing sustained recovery throughout the survivorship continuum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.